Nifurtimox

Drug Profile

Nifurtimox

Alternative Names: Bay-2502; Lampit; NECT; Nifurtimox-eflornithine combination therapy

Latest Information Update: 17 Nov 2016

Price : $50

At a glance

  • Originator Bayer
  • Developer Bayer; Drugs for Neglected Diseases Initiative Foundation
  • Class Antiprotozoals; Nitrofurans; Small molecules; Thiamorpholines; Thiazines
  • Mechanism of Action Protozoan protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Trypanosomiasis
  • Phase III Chagas disease

Most Recent Events

  • 01 Aug 2016 Bayer completes a phase I trial in Chagas' disease in Argentina (NCT02606864)
  • 01 Jan 2016 Phase-III clinical trials in Chagas' disease (In infants, In children, In adolescents) in Argentina, Bolivia (PO) (NCT02625974) after January 2016
  • 01 Jan 2016 Phase-III clinical trials in Chagas' disease (In infants, In children, In adolescents) in Colombia (PO) (NCT02625974)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top